Oncology News & Perspectives
Categories
Featured Exclusive
Presented at ESMO Virtual Congress 2020, a recent study compared results on apalutamide administered in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) between real-world data from an international named patient program (NPP) and the phase 3 SPARTAN clinical trial and found that the results were similar. In an interview with i3 Health, lead study author Professor Heather...
Top Oncology Stories
Wednesday, September 23, 2020
Presented at ESMO Virtual Congress 2020, a recent study compared results on apalutamide administered in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) between real-world da...
Tuesday, September 22, 2020
Nivolumab/ipilimumab prolongs treatment-free survival with and without toxicity in patients with untreated advanced renal cell carcinoma (RCC), according to an updated analysis of the phase 3 CheckMat...
Monday, September 21, 2020
Olaparib prolongs overall survival compared with enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) and gene alterations in BRCA1, BRCA2, or ATM, acco...
Friday, September 18, 2020
The COVID-19 pandemic has impacted multiple aspects of oncology, including patient care, research, continuing medical education (CME), and cancer care providers' psychological well-being, according to...
Thursday, September 17, 2020
The addition of atezolizumab to bevacizumab/carboplatin/paclitaxel (BCP) significantly prolongs overall survival in patients with non-squamous non-small cell lung cancer (NSCLC) with epidermal growth ...
Wednesday, September 16, 2020
In a recent study presented at ESMO Virtual Congress 2020, data reported on apalutamide (APA) administered in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) is comparable b...
Most Popular
Expert Perspectives
Presented at ESMO Virtual Congress 2020, a recent study compared results on apalutamide administered in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) between real-world data from an international named patient program (NP...
Gastric or gastroesophageal junction (G/GEJ) cancer constitutes the third leading cause of cancer death worldwide, and more therapeutic options are needed. In results from the phase 3 KEYNOTE-062 study, published last week in JAMA Oncology, Kohei Shi...
Due to intensive treatments, severe side effects, and a high rate of recurrence, oral cavity squamous cell carcinoma (SCC) is a challenging disease associated with poor outcomes. According to a recent study, neoadjuvant nivolumab alone or in combinat...
While patients with cancer are at an increased risk of experiencing poor outcomes from COVID-19, there is significant variability in COVID-19 risk and mortality among patients with different tumor types and demographics such as age and sex, with thos...
According to a recent study, led by Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, dabrafenib in combination with trametinib is an effective treatment option for patients with BRAFV600E -mutated biliary tract cancer (BTC). I...
Original Research
Pre-activity assessment data from i3 Health's nursing continuing professional development (NCPD) activity "Understanding and Optimizing CAR T-Cell Therapy for Patients With B-Cell Malignancies" has revealed significant baseline knowledge gaps regardi...
At the 67th Society of Government Service Urologists (SGSU) Kimbrough Urological Seminar, held from January 15th to 19th, 2020, in Charlotte, North Carolina, i3 Health conducted a survey of participants regarding the formats in which they wished to r...
Pre-activity assessment data from i3 Health's continuing medical education (CME)/continuing nursing education (CNE) activity "Optimizing the Management of Advanced Cervical Cancer With Checkpoint Inhibitor Therapy" has revealed significant baseline k...
Due to the increase in treatment options for castration-resistant prostate cancer (CRPC) in recent years, some confusion exists over the optimal therapeutic approach. A number of factors must be considered in CRPC treatment, including patient health ...
Optimal management of carcinoid syndrome in patients with neuroendocrine tumors poses a challenge, due to the fact that the primary symptoms of carcinoid syndrome are associated with more common diseases. Because timely recognition is difficult, symp...
